BRAF and amyotrophic lateral sclerosis: We further found that these culture systems could predict neuroprotective targets discovered in other ALS models, and identified several novel neuroprotective agents, including a PKC inhibitor Enzastaurin and an FDA approved BRAF inhibitor GDC-0879.